Related Experiment Video
Updated: Aug 5, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Distribution of Hypo- and Hyperglycemic Event Duration in Type 1 Diabetes Using Automated Insulin Delivery
Ermina Bach1,2, Sanne Fisker2, Mia Christensen3
1Medical Diagnostic Center, Viborg Regional Hospital, Denmark.
Journal of Diabetes Science and Technology
|July 30, 2026
Summary
Automated insulin delivery (AID) systems show varying impacts on glucose control in type 1 diabetes. One system, MiniMed 780G, was linked to longer hypoglycemic event durations compared to Tandem Control IQ.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Biomedical Engineering
Background:
- Type 1 diabetes management increasingly utilizes automated insulin delivery (AID) systems.
- Evaluating glucose event distribution and duration provides deeper insights beyond time-in-range metrics.
Purpose of the Study:
- To compare the distribution and duration of hypoglycemic and hyperglycemic events between two leading AID systems: Tandem Control IQ (CIQ) and MiniMed 780G (MM).
Main Methods:
- Continuous glucose monitoring data from 83 CIQ users and 65 MM users over 60 days were analyzed.
- Frequency and duration of hypoglycemia (<70 mg/dL) and hyperglycemia (>180 mg/dL) were calculated.
- Hypoglycemic event duration was analyzed in 15-120 minute increments; hyperglycemic events in 15-430 minute increments.
Main Results:
- No significant difference in the number of hypoglycemic events between CIQ (28) and MM (23).
- Hypoglycemic events were 15% longer with MM (35 min) than CIQ (30 min) (P < .001).
- No significant difference in hyperglycemic event duration between MM (85 min) and CIQ (90 min).
Conclusions:
- Analysis of event duration complements time-in-range data for AID system evaluation.
- The MiniMed 780G system was associated with a longer duration of hypoglycemic events compared to the Tandem Control IQ system.
- Further research is needed to understand the clinical implications of differing event durations across AID systems.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...